ES2208167T3 - PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE. - Google Patents
PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE.Info
- Publication number
- ES2208167T3 ES2208167T3 ES00105011T ES00105011T ES2208167T3 ES 2208167 T3 ES2208167 T3 ES 2208167T3 ES 00105011 T ES00105011 T ES 00105011T ES 00105011 T ES00105011 T ES 00105011T ES 2208167 T3 ES2208167 T3 ES 2208167T3
- Authority
- ES
- Spain
- Prior art keywords
- fluorophenyl
- chlorodiphenylphosphine
- reaction
- methyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- -1 4-FLUOROPHENYL Chemical class 0.000 title abstract description 7
- XGRJZXREYAXTGV-UHFFFAOYSA-N chlorodiphenylphosphine Chemical compound C=1C=CC=CC=1P(Cl)C1=CC=CC=C1 XGRJZXREYAXTGV-UHFFFAOYSA-N 0.000 claims abstract description 24
- MSDYDUNHTAYBHV-UHFFFAOYSA-N n-[4-(4-fluorophenyl)-5-(hydroxymethyl)-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1CO MSDYDUNHTAYBHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- CVRDGWDBQZPJJI-UHFFFAOYSA-N n-[5-(diphenylphosphorylmethyl)-4-(4-fluorophenyl)-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical compound C=1C=CC=CC=1P(=O)(C=1C=CC=CC=1)CC=1C(C(C)C)=NC(N(C)S(C)(=O)=O)=NC=1C1=CC=C(F)C=C1 CVRDGWDBQZPJJI-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 239000002585 base Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims 1
- 150000008046 alkali metal hydrides Chemical class 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000003444 phase transfer catalyst Substances 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 18
- 238000001816 cooling Methods 0.000 description 15
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000007844 bleaching agent Substances 0.000 description 5
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 5
- 229940072033 potash Drugs 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 235000009518 sodium iodide Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procedimiento para la preparación de N-[5-(di- fenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la **fórmula** caracterizado porque se hace reaccionar [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil- amino)pirimidin--5-il] metanol de la fórmula con clorodifenilfosfina.Procedure for the preparation of N- [5- (di-phenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the ** formula ** characterized in that it is reacted [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol of the formula with chlorodiphenylphosphine.
Description
Procedimiento para la preparación de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetano-sulfonamida.Procedure for the preparation of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethane-sulfonamide.
La presente invención se refiere a un procedimiento para la preparación de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetano-sulfonamida de la fórmulaThe present invention relates to a procedure for the preparation of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethane-sulfonamide of the formula
La
N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida
(I), que
puede prepararse de acuerdo con la invención, es un
producto intermedio para la preparación de principios
farmacéuticamente activos, por ejemplo de inhibidores de la
HMG-Co A reductasa (Bioorg. Med. Che. 1997, 5,
437).N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide (I), which
It can be prepared according to the invention, it is an intermediate product for the preparation of pharmaceutically active ingredients, for example of HMG-Co A reductase inhibitors (Bioorg. Med. Che. 1997, 5, 437).
La misión de la invención consistía en encontrar un acceso mejorado al producto intermedio antes citado.The mission of the invention was to find improved access to the intermediate product mentioned above.
El problema podía resolverse con el nuevo procedimiento según la reivindicación 1.The problem could be solved with the new method according to claim 1.
De acuerdo con la invención la preparación de la N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la fórmula (I) se efectúa por reacción de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol de la fórmula (II)According to the invention the preparation of the N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the formula (I) is carried out by reaction of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol of the formula (II)
con clorodifenilfosfina.with chlorodiphenylphosphine
Una importante ventaja de la síntesis de acuerdo con la invención es su disponibilidad a gran escala.An important advantage of the agreement synthesis With the invention is its large-scale availability.
El [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol de la fórmula (II) es accesible de manera fácil por reducción del correspondiente éster con, p. ej., hidruro de di-isobutilamino (documento EP-A-0521471).The [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol of the formula (II) is easily accessible by reducing the corresponding ester with, p. eg hydride of di-isobutylamino (document EP-A-0521471).
La reacción de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol de la fórmula (II) con clorodifenilfosfina puede efectuarse bien directamente o a través de una desprotonización previa. Se prefiere la reacción directa con clorodifenilfosfina, con subsiguiente tratamiento con una base.The reaction of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol of the formula (II) with chlorodiphenylphosphine can be carried out well directly or through prior deprotonization. It preferred direct reaction with chlorodiphenylphosphine, with subsequent base treatment.
Según la variante "desprotonización" se mezcla el [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-ami- no)pirimidin-5-il]metanol de la fórmula (II) convenien-temente con un agente desprotonizador habitual en el sector técnico, ventajosamente con un hidruro de álcali o un hexaalquildisilazano alcalino. Se emplea preferentemente hidruro de sodio.According to the "deprotonization" variant mix the [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-ami- no) pyrimidin-5-yl] methanol of formula (II) conveniently with an agent Deprotonizer usual in the technical sector, advantageously with an alkali hydride or an alkaline hexaalkyldisilazane. Is used preferably sodium hydride.
Habitualmente, la desprotonización se realiza a la temperatura ambiente. Después de esto se efectúa la reacción con clorodifenilfosfina. La reacción con clorodifenilfosfina se realiza convenientemente a una temperatura entre 80ºC y 200ºC.Usually, deprotonization is performed at ambient temperature After this the reaction is carried out with chlorodiphenylphosphine The reaction with chlorodiphenylphosphine is carried out conveniently at a temperature between 80 ° C and 200 ° C.
La clorodifenilfosfina puede actuar directamente como disolvente. No obstante, es posible emplear adicionalmente un disolvente inerte de punto de ebullición lo más elevado posible, tal como p. ej. tolueno o xileno o decalina, así como las correspondientes mezclas de isómeros.Chlorodiphenylphosphine can act directly as a solvent However, it is possible to additionally use a inert boiling point solvent as high as possible, as p. ex. toluene or xylene or decalin, as well as corresponding mixtures of isomers.
La reacción puede producirse en presencia de un catalizador. Como catalizador son apropiados yodo, yoduros alcalinos tales como, p. ej., yoduro de sodio o potasio, los halogenuros de alquilo tales como, p. ej., yoduro de metilo o de etilo, o los alcanos dihalogenados tales como, p. ej., el dibromometano. Se emplea preferentemente un yoduro alcalino. La cantidad de catalizador se elige habitualmente en el intervalo de 1% en mol a 20% en moles, referido al alcohol empleado de la fórmula II.The reaction may occur in the presence of a catalyst. Iodine, iodides are suitable as catalyst alkalis such as, e.g. e.g., sodium or potassium iodide, alkyl halides such as, e.g. e.g., methyl or iodide ethyl, or dihalogenated alkanes such as, e.g. eg the dibromomethane An alkaline iodide is preferably used. The amount of catalyst is usually chosen in the range of 1% in mol to 20% in moles, based on the alcohol used by the formula II
La reacción según la variante directa transcurre convenientemente a una temperatura de -20ºC a 130ºC, preferentemente de +20ºC a 120ºC.The reaction according to the direct variant takes place conveniently at a temperature of -20ºC to 130ºC, preferably from + 20 ° C to 120 ° C.
La clorodifenilfosfina puede, según la variante "desprotonización", actuar directamente como disolvente. No obstante, es posible emplear adicionalmente un disolvente inerte de punto de ebullición lo más elevado posible, tal como p. ej. toluno o xileno o decalina, así como las correspondientes mezclas de isómeros.Chlorodiphenylphosphine can, depending on the variant "deprotonization", act directly as a solvent. Do not However, it is possible to additionally use an inert solvent of boiling point as high as possible, such as p. ex. toluno or xylene or decalin, as well as the corresponding mixtures of isomers
A continuación de la reacción con clorodifenilfosfina se combina la mezcla de reacción con una base. Son bases apropiadas los hidróxidos alcalinos o los carbonatos alcalinos tales como, p. ej., una solución acuosa de hidróxido sódico o potásico, o de carbonato sódico o potásico.Following the reaction with Chlorodiphenylphosphine combines the reaction mixture with a base. Alkaline hydroxides or carbonates are appropriate bases alkalis such as, e.g. eg, an aqueous hydroxide solution sodium or potassium, or sodium or potassium carbonate.
Eventualmente, para acelerar la reacción con la base ppuede emplearse un catalizado habitual de transferencia de fases tal como, p. ej., un halogenuro de tetraalquilamonio. Se pueden lograr también buenos resultados mediante la aplicación de éteres corona.Eventually, to speed up the reaction with the base can be used a usual transfer catalytic phases such as, e.g. eg, a tetraalkylammonium halide. I know they can also achieve good results by applying crown ethers
La N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida de la fórmula I puede aislarse, una vez terminada la reacción, de manera conocida por el personal técnico, p. ej. mediante extracción con un disolvente apropiado de la mezcla de reacción, así como por cristalización en la mezcla.The N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide of the formula I can be isolated, once the reaction is over, from way known to technical staff, p. ex. by extraction with an appropriate solvent of the reaction mixture, as well as by crystallization in the mixture.
Se dispusieron en 5 ml de cis/trans-decalina 1,00 g (2,83 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol y se mezclaron con 204 mg (4,68 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 30 min a la temperatura ambiente se añadieron bajo agitación vigorosa durante 6 min 680 mg (2,93 milimoles) de clorodifenilfosfi-na. Se mezcló con 52,2 mg (0,35 milimoles) de yoduro sódico y se calentó durante 2 h 15 min hasta 184-186ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 50 ml de solución de hidrógeno-sulfito sódico al 38-40% y 50 ml de acetato de etilo. Se separó la fase orgánica y la fase acuosa se extrajo con 50 ml de acetato de etilo. Las fases orgánicas reunidas se secaron sobre sulfato magnésico y se concentró al vacío. Se obtuvieron 1,74 g de producto bruto que se purificaron mediante cromatografía a través de gel de sílice (eluyente: n-hexano/acetato de etilo 1:2). Se obtuvieron 382,4 mg (25,1%) de N-[5-(difenilfosfino-ilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-me-tilmetanosulfonamida en forma de un sólido incoloro. (Punto de fusión 184 - 185ºC).They were placed in 5 ml of cis / trans-decalin 1.00 g (2.83 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol and mixed with 204 mg (4.68 mmol) of sodium hydride (55% dispersion in mineral oil). After 30 min at room temperature was added under vigorous stirring for 6 min 680 mg (2.93 mmol) of chlorodiphenylphosphine It was mixed with 52.2 mg (0.35 millimoles) of sodium iodide and heated for 2 h 15 min until 184-186 ° C. After cooling to temperature ambient was mixed with 50 ml of solution 38-40% sodium hydrogen sulphite and 50 ml of ethyl acetate. The organic phase and the phase were separated Aqueous was extracted with 50 ml of ethyl acetate. Phases The combined organics were dried over magnesium sulfate and concentrated under vacuum 1.74 g of crude product were obtained and purified. by chromatography through silica gel (eluent: n-hexane / ethyl acetate 1: 2). 382.4 were obtained mg (25.1%) of N- [5- (diphenylphosphino-ylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-me-tilmethanesulfonamide in the form of a colorless solid. (Melting point 184-185 ° C).
\newpage\ newpage
Se dispusieron en 4,5 ml de xileno (mezcla de isómeros) 282,8 mg (0,80 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 55 mg (1,30 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 35 min se añadieron a temperatura ambiente, bajo agitación vigorosa, durante 5 min 185 mg (0,84 milimoles) de clorodifenilfosfina en 1,5 ml de xileno y, a continuación, se calentó durante 20 h hasta 135ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 15 ml de agua y se extrajo con 10 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 2 x 10 ml de acetato de etilo. A continuación se secaron las fases orgánicas reunidas (MgSO_{4}) y se concentró al vacío. Se obtuvieron 510 mg de producto bruto, que se purificó por cromatografía sobre gel de sílice (eluyente: n-hexano/acetato de etilo 1 : 2, luego acetato de etilo) y se aislaron 230 mg (53,5%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2- il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were placed in 4.5 ml of xylene (mixture of isomers) 282.8 mg (0.80 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 55 mg (1.30 mmol) of sodium hydride (55% dispersion in mineral oil). After 35 min it added at room temperature, under vigorous stirring, for 5 min 185 mg (0.84 mmol) of chlorodiphenylphosphine in 1.5 ml of xylene and then heated for 20 h at 135 ° C. After cooling to room temperature, it was mixed with 15 ml of water and extracted with 10 ml of ethyl acetate. The phase The organic was separated and the aqueous phase was extracted with 2 x 10 ml of ethyl acetate. The organic phases were dried pooled (MgSO4) and concentrated in vacuo. 510 mg were obtained of crude product, which was purified by gel chromatography of silica (eluent: n-hexane / ethyl acetate 1: 2, then ethyl acetate) and 230 mg (53.5%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2- il] -N-methylmethanesulfonamide in form of a colorless solid.
Se dispusieron previamente en 8 ml de tolueno 512 mg (1,45 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 96 mg (2,20 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 1 h se añadieron a la temperatura ambiente bajo agitación vigorosa durante 5 min 333,5 mg (1,44 milimoles) de clorodifenilfos-fina en 2,5 ml de tolueno. Se mezcló con 28,7 mg (0,19 milimoles) de yoduro sódico y se calentó durante 22 h hasta 108ºC. Después de 6 h se mezcló con otros 28,7 mg (0,19 milimoles) de yoduro sódico. Después de enfriar hasta la temperatura ambiente se mezcló con 30 ml de solución de hidrógeno-sulfito sódico al 38-40% y se extrajo con 50 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 50 ml de acetato de etilo. A continuación se concentraron al vacío las fases orgánicas reunidas. Se obtuvieron 740 mg de producto bruto, que mediante cromatografía sobre gel de sílice (eluyente: acetato de etilo) se purificaron y se aislaron 212,7 mg (27,3%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were previously placed in 8 ml of toluene 512 mg (1.45 millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 96 mg (2.20 mmol) of sodium hydride (55% dispersion in mineral oil). After 1 h they were added to ambient temperature under vigorous stirring for 5 min 333.5 mg (1.44 mmol) of chlorodiphenylphosphine in 2.5 ml of toluene It was mixed with 28.7 mg (0.19 mmol) of iodide sodium and heated for 22 h to 108 ° C. After 6 h it mixed with another 28.7 mg (0.19 millimoles) of sodium iodide. After cooling to room temperature was mixed with 30 ml of sodium hydrogen sulphite solution at 38-40% and extracted with 50 ml of ethyl acetate. The organic phase was separated and the aqueous phase was extracted with 50 ml of ethyl acetate. The phases were then concentrated in vacuo Organic gathered. 740 mg of crude product were obtained, which by chromatography on silica gel (eluent: acetate ethyl) were purified and 212.7 mg (27.3%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Se dispusieron en 8 ml de xileno (mezcla de isómeros) 502,6 mg (1,42 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonilamino)pirimidin-5-il]metanol y se mezclaron con 96,6 mg (2,21 milimoles) de hidruro sódico (dispersión al 55% en aceite mineral). Después de 1 h se añadieron a la temperatura ambiente, bajo agitación vigorosa y durante 5 min, 340,8 mg (1,47 milimoles) de clorodifenil-fosfina en 2,5 ml de xileno. Se mezclaron con 34,6 mg (0,23 milimoles) de yoduro sódico y se calentó durante 19 h hasta 136ºC. Después de 3 h se mezclaron con otros 25,1 mg de yoduro sódico. Después de enfriar hasta la temperatura ambiente se mezcló con 30 ml de solución diluida de hidrógeno-sulfito sódico y se extrajo con 50 ml de acetato de etilo. La fase orgánica se separó y la fase acuosa se extrajo con 50 ml de acetato de etilo. A continuación se concentraron al vacío las fases orgánicas reunidas. Se obtuvieron 906 mg de producto bruto, que se purificó por cromatografía sobre gel de sílice (eluyente: acetato de etilo), y se aislaron 315,9 mg (41,3%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.They were placed in 8 ml of xylene (mixture of isomers) 502.6 mg (1.42 mmol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonylamino) pyrimidin-5-yl] methanol and mixed with 96.6 mg (2.21 mmol) of sodium hydride (55% dispersion in mineral oil). After 1 h they were added to room temperature, under vigorous stirring and for 5 min, 340.8 mg (1.47 mmol) of chlorodiphenyl phosphine in 2.5 ml of xylene. They were mixed with 34.6 mg (0.23 mmol) of sodium iodide and heated for 19 h to 136 ° C. After 3 h mixed with another 25.1 mg of sodium iodide. After cooling until room temperature was mixed with 30 ml of solution diluted sodium hydrogen sulphite and extracted with 50 ml of ethyl acetate. The organic phase was separated and the phase Aqueous was extracted with 50 ml of ethyl acetate. Then you concentrated the combined organic phases in vacuo. They were obtained 906 mg of crude product, which was purified by chromatography on silica gel (eluent: ethyl acetate), and 315.9 mg were isolated (41.3%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Ejemplo 5 (reacción directa)Example 5 (reaction direct)
Se dispusieron en 7 g de tolueno bajo enfriamiento con baño de hielo 1,05 g (2,95 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol y se mezclaron bajo agitación con 820 mg (3,69 milimoles) de clorodifenilfosfina. Se calentó durante 3 h hasta 108ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 553 mg (4,43 milimoles) de lejía acuosa de potasa (al 45%) y 97,5 mg (0,29 milimoles) de bromuro de tetrabutilamonio y se agitó fuertemente durante 1 h a 60ºC. La fuente de calor se retiró y la mezcla de reacción, todavía caliente, se mezcló con 20 ml de agua. Se dejó enfriar lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría y tolueno y se secó al vacío a 40ºC. Se aislaron 1,04 g (64,1%; contenido: 97,6%) de N-[5- (difenilfosfinoil-metil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metil-metanosulfonamida en forma de un sólido incoloro.They were placed in 7 g of low toluene 1.05 g (2.95 mmol) ice bath cooling [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol and mixed under stirring with 820 mg (3.69 mmol) of chlorodiphenylphosphine It was heated for 3 h at 108 ° C. After cool to room temperature, mixed with 553 mg (4.43 millimoles) of aqueous lye from potash (45%) and 97.5 mg (0.29 millimoles) of tetrabutylammonium bromide and stirred strongly for 1 h at 60 ° C. The heat source was removed and the mixture of reaction, still hot, was mixed with 20 ml of water. Left cool slowly to 4 ° C and the solid was filtered off precipitate. The product was washed with cold water and toluene and was dried under vacuum at 40 ° C. 1.04 g (64.1%; content: 97.6%) of N- [5- (diphenylphosphinoyl-methyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methyl-methanesulfonamide in the form of a colorless solid.
Ejemplo 6 (reacción directa)Example 6 (reaction direct)
Se dispusieron en 13 g de tolueno 2,03 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)pirimidin-5-il]metanol y bajo enfriamiento con baño de hielo se mezclaron con 1,67 g (7,51 milimoles) de clorodifenilfosfina en 2 g de tolueno. Se calentó durante 2,5 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,08 g (8,66 milimoles) de una lejía de potasa al 45% y 175 mg (0,574 milimoles) de cloruro de tetrabutilamonio y se agitó fuertemente durante 2 h a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,66 g (84,1%; contenido: 96,6%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.03 g (5.69 were placed in 13 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol and under ice bath cooling they were mixed with 1.67 g (7.51 mmol) of chlorodiphenylphosphine in 2 g of toluene. I know heated for 2.5 h to 111 ° C. After cooling to room temperature was mixed with 1.08 g (8.66 mmol) of a 45% potash bleach and 175 mg (0.574 mmol) of tetrabutylammonium and stirred strongly for 2 h at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.66 g (84.1%; content: 96.6%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Ejemplo 7 (reacción directa)Example 7 (reaction direct)
Se dispusieron en 13,1 g de tolueno 2,02 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol y bajo enfriamiento con baño de hielo se mezclaron con 1,67 g (7,51 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 3 h hasta 109ºC. Después de enfriar hasta la temperatura ambiente, se mezcló con 590 mg (8,94 milimoles) de hidróxido potásico sólido y 159 mg (0,582 milimoles) de 18-corona-6 y se agitó fuertemente durante 3,5 h a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y con tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 1,82 g (59,5%; contenido: 95,9%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.02 g (5.69 were placed in 13.1 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol and under ice bath cooling they were mixed with 1.67 g (7.51 millimoles) of chlorodiphenylphosphine in 1.9 g of toluene. It got hot for 3 h at 109 ° C. After cooling to temperature ambient, mixed with 590 mg (8.94 mmol) of hydroxide solid potassium and 159 mg (0.582 mmol) of 18-crown-6 and stirred heavily for 3.5 h at 60 ° C. To the hot reaction mixture were added 30 ml of water It was stirred briefly at 60 ° C, cooled slowly to 4 ° C and the precipitated solid was filtered off. The product was washed with cold water (10 ml) and with cold toluene (10 ml) and dried under vacuum at 40 ° C. 1.82 g (59.5%; content: 95.9%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Ejemplo 8 (reacción directa)Example 8 (reaction direct)
Se dispusieron en 13,1 g de tolueno 2,05 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol, y bajo enfria- miento con baño de hielo se mezclaron con 1,71 g (7,69 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 2,5 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,17 g (8,78 milimoles) de lejía de sosa al 30% y 182 mg (0,597 milimoles) de cloruro de tetrabutilamonio y se agitó fuertemente durante 3,5 h a 60ºC. A la mezcla de reacción caliente se agregaron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,18 g (71,3%; contenido: 97,3%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropil-pirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro (Punto de fusión 184-185ºC).2.05 g (5.69 were placed in 13.1 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol, and under ice bath cooling they were mixed with 1.71 g (7.69 mmol) of chlorodiphenylphosphine in 1.9 g of toluene. I know heated for 2.5 h to 111 ° C. After cooling to room temperature was mixed with 1.17 g (8.78 mmol) of bleach 30% soda and 182 mg (0.597 mmol) of chloride tetrabutylammonium and stirred vigorously for 3.5 h at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.18 g (71.3%; content: 97.3%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropyl-pyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid (Melting Point 184-185 ° C).
Ejemplo 9 (reacción directa)Example 9 (reaction direct)
Una suspensión de 9,29 g (26,3 milimoles) de de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino) pirimidin-5-il]metanol en 26 g de tolueno se mezcló bajo enfriamiento con baño de hielo con 7,64 g (34,4 milimoles) de clorodifenilfosfina. Se lavó con un poco de tolueno y se calentó durante 2 h hasta 111ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 4,94 g de una lejía de potasa al 45% y 873 mg (2,71 milimoles) de bromuro de tetrabutilamonio y se agitó fuertemente durante 1 h a 60ºC. A la mezcla de reacción caliente se añadieron 100 ml de agua. Se agitó brevemente a 60ºC, se dejó enfriar lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (30 ml) y tolueno frío (30 ml) y se secó al vacío a 40ºC. Se aislaron 11,74 g (78,4%; contenido: 94,4%) de N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incolor.A suspension of 9.29 g (26.3 mmol) of of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol in 26 g of toluene was mixed under ice bath cooling with 7.64 g (34.4 mmol) of chlorodiphenylphosphine. He washed with a little toluene and heated for 2 h to 111 ° C. After cooling until room temperature was mixed with 4.94 g of a bleach of 45% potash and 873 mg (2.71 mmol) of bromide tetrabutylammonium and stirred strongly for 1 h at 60 ° C. To Hot reaction mixture was added 100 ml of water. It stirred briefly at 60 ° C, allowed to cool slowly to 4 ° C and separated by filtration the precipitated solid. The product was washed with water cold (30 ml) and cold toluene (30 ml) and dried under vacuum at 40 ° C. I know isolated 11.74 g (78.4%; content: 94.4%) of N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Ejemplo 10 (reacción directa sin catalizador de transferencia de fases)Example 10 (direct reaction without catalyst transfer of phases)
Se dispusieron en 13 g de tolueno 2,03 g (5,69 milimoles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino)-pirimidin-5-il]metanol, y bajo enfriamiento con baño de hielo se mezclaron con 1,69 g (7,60 milimoles) de clorodifenilfosfina en 1,9 g de tolueno. Se calentó durante 2,5 h hasta 109ºC. Después de enfriar hasta la temperatura ambiente se mezcló con 1,09 g (8,74 milimoles) de lejía de potasa al 45% y se agitó fuertemente durante 2 h 45 minutos a 60ºC. A la mezcla de reacción caliente se añadieron 30 ml de agua. Se agitó brevemente a 60ºC, se enfrió lentamente hasta 4ºC y se separó por filtración el sólido precipitado. El producto se lavó con agua fría (10 ml) y tolueno frío (10 ml) y se secó al vacío a 40ºC. Se aislaron 2,44 g (76,8%; contenido: 99,1%) de [N-[5-(difenilfosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro.2.03 g (5.69 were placed in 13 g of toluene) millimoles) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) -pyrimidin-5-yl] methanol, and under ice bath cooling they were mixed with 1.69 g (7.60 millimoles) of chlorodiphenylphosphine in 1.9 g of toluene. It got hot for 2.5 h at 109 ° C. After cooling to temperature ambient was mixed with 1.09 g (8.74 mmol) of potash bleach at 45% and stirred vigorously for 2 h 45 minutes at 60 ° C. To Hot reaction mixture was added 30 ml of water. It stirred briefly at 60 ° C, slowly cooled to 4 ° C and separated by filtration the precipitated solid. The product was washed with cold water (10 ml) and cold toluene (10 ml) and dried under vacuum at 40 ° C. I know isolated 2.44 g (76.8%; content: 99.1%) of [N- [5- (diphenylphosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid.
Ejemplo 11 (reacción directa)Example 11 (reaction direct)
Una solución de 60,08 g (0,170 moles) de [4-(4-fluorofenil)-6-isopropil-2-(N-metil-N-metilsulfonil-amino) pirimidin-5-il]metanol en aproximadamente 485 ml de tolueno se mezcló a 60ºC con 42,55 g (0,192 moles; contenido: 99,7%) de clorodifenilfosfina. Se agitó durante 2,5 horas y se agregó esta solución a una mezcla, caliente a 60ºC, a base de 70,66 g de lejía de potasa (al 20%) y 5,04 g (0,017 moles) de cloruro de tetrabutilamonio, y se lavó a continuación con 13 ml de tolueno. Se agitó durante 2 h a 60ºC y se añadieron 215 ml de agua y 108 ml de tolueno. Aproximadamente a 80ºC se separó la fase acuosa y se extrajo la fase orgánica todavía dos veces con 215 ml de agua caliente cada vez. Se deshidrató por vía azeotropa en el separador de agua y se dejó enfriar durante 2 h hasta 0ºC. Los cristales precipitados se separaron por filtración y se lavaron 2 veces con 160 ml de tolueno. Después de secar al vacío a 40ºC se obtuvieron 81,94 g (89,7%) de N-[5-(difenil-fosfinoilmetil)-4-(4-fluorofenil)-6-isopropilpirimidin-2-il]-N-metilmetanosulfonamida en forma de un sólido incoloro [contenido (según HPLC): 100%].A solution of 60.08 g (0.173 mol) of [4- (4-fluorophenyl) -6-isopropyl-2- (N-methyl-N-methylsulfonyl-amino) pyrimidin-5-yl] methanol in approximately 485 ml of toluene was mixed at 60 ° C with 42.55 g (0.192 moles; content: 99.7%) of chlorodiphenylphosphine. It stirred for 2.5 hours and this solution was added to a mixture, hot at 60 ° C, based on 70.66 g of potash bleach (20%) and 5.04 g (0.017 mol) of tetrabutylammonium chloride, and washed at then with 13 ml of toluene. It was stirred for 2 h at 60 ° C and was they added 215 ml of water and 108 ml of toluene. About 80 ° C the aqueous phase was separated and the organic phase was still extracted twice with 215 ml of hot water each time. He became dehydrated by azeotroped in the water separator and allowed to cool for 2 h up to 0 ° C. The precipitated crystals were filtered off and they were washed twice with 160 ml of toluene. After drying under vacuum at 40 ° C 81.94 g (89.7%) of N- [5- (diphenyl-phosphinoylmethyl) -4- (4-fluorophenyl) -6-isopropylpyrimidin-2-yl] -N-methylmethanesulfonamide in the form of a colorless solid [content (according to HPLC): 100%].
Claims (10)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99104786 | 1999-03-10 | ||
EP99104786 | 1999-03-10 | ||
EP99104785 | 1999-03-10 | ||
EP99104785 | 1999-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2208167T3 true ES2208167T3 (en) | 2004-06-16 |
Family
ID=26152921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES00105011T Expired - Lifetime ES2208167T3 (en) | 1999-03-10 | 2000-03-09 | PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1035127B1 (en) |
JP (1) | JP4438167B2 (en) |
KR (1) | KR100586664B1 (en) |
CN (1) | CN1126755C (en) |
AT (1) | ATE251633T1 (en) |
CA (1) | CA2300243C (en) |
CZ (1) | CZ298235B6 (en) |
DE (1) | DE50003959D1 (en) |
DK (1) | DK1035127T3 (en) |
ES (1) | ES2208167T3 (en) |
HK (1) | HK1029996A1 (en) |
HU (1) | HU224967B1 (en) |
NO (1) | NO324982B1 (en) |
PL (1) | PL195166B1 (en) |
PT (1) | PT1035127E (en) |
SK (1) | SK284027B6 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0311195A (en) * | 2002-05-21 | 2005-02-22 | Ranbaxy Lab Ltd | Rosuvastatin Preparation Process |
US7341743B2 (en) | 2004-10-28 | 2008-03-11 | Revlon Consumer Products Corporation | Color cosmetic compositions |
WO2009143776A1 (en) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | Preparation method of rosuvastatin calcium and its intermediates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
-
2000
- 2000-03-07 SK SK332-2000A patent/SK284027B6/en not_active IP Right Cessation
- 2000-03-07 CZ CZ20000837A patent/CZ298235B6/en not_active IP Right Cessation
- 2000-03-09 CA CA002300243A patent/CA2300243C/en not_active Expired - Lifetime
- 2000-03-09 ES ES00105011T patent/ES2208167T3/en not_active Expired - Lifetime
- 2000-03-09 EP EP00105011A patent/EP1035127B1/en not_active Expired - Lifetime
- 2000-03-09 AT AT00105011T patent/ATE251633T1/en active
- 2000-03-09 PT PT00105011T patent/PT1035127E/en unknown
- 2000-03-09 DK DK00105011T patent/DK1035127T3/en active
- 2000-03-09 DE DE50003959T patent/DE50003959D1/en not_active Expired - Lifetime
- 2000-03-09 NO NO20001228A patent/NO324982B1/en not_active IP Right Cessation
- 2000-03-10 HU HU0001127A patent/HU224967B1/en unknown
- 2000-03-10 PL PL338944A patent/PL195166B1/en unknown
- 2000-03-10 CN CN00103783A patent/CN1126755C/en not_active Expired - Lifetime
- 2000-03-10 KR KR1020000012002A patent/KR100586664B1/en not_active IP Right Cessation
- 2000-03-10 JP JP2000066084A patent/JP4438167B2/en not_active Expired - Lifetime
-
2001
- 2001-02-08 HK HK01100875A patent/HK1029996A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CZ2000837A3 (en) | 2000-10-11 |
CZ298235B6 (en) | 2007-08-01 |
HUP0001127A3 (en) | 2003-07-28 |
NO20001228D0 (en) | 2000-03-09 |
JP4438167B2 (en) | 2010-03-24 |
CA2300243A1 (en) | 2000-09-10 |
PT1035127E (en) | 2004-02-27 |
KR100586664B1 (en) | 2006-06-07 |
NO20001228L (en) | 2000-09-11 |
CA2300243C (en) | 2009-12-29 |
HK1029996A1 (en) | 2001-04-20 |
KR20010006773A (en) | 2001-01-26 |
JP2000309595A (en) | 2000-11-07 |
CN1126755C (en) | 2003-11-05 |
DE50003959D1 (en) | 2003-11-13 |
HU0001127D0 (en) | 2000-05-28 |
SK284027B6 (en) | 2004-08-03 |
EP1035127B1 (en) | 2003-10-08 |
HUP0001127A2 (en) | 2001-06-28 |
HU224967B1 (en) | 2006-04-28 |
EP1035127A1 (en) | 2000-09-13 |
NO324982B1 (en) | 2008-01-14 |
PL338944A1 (en) | 2000-09-11 |
PL195166B1 (en) | 2007-08-31 |
SK3322000A3 (en) | 2000-10-09 |
ATE251633T1 (en) | 2003-10-15 |
DK1035127T3 (en) | 2003-11-03 |
CN1272499A (en) | 2000-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2316349T3 (en) | PROCEDURE FOR THE PRODUCTION OF (E) - (6- (2- (4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- (METHYL (METILSULFONYL) AMINO) PIRIMIDIN -5-IL) VINYL) (4R, 6S) -2,2-DIMETHYL (1,3) DIOXAN-4-IL) TERC-BUTILO ACETATE. | |
AU2014373961B2 (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1H)-one and processes for their preparation | |
ES2612033T3 (en) | Bosentan preparation procedure | |
ES2376375T3 (en) | PROCEDURE FOR PREPARATION OF BOSENT�? N. | |
WO2016082605A1 (en) | Method for preparing palbociclib | |
TW533204B (en) | A process for preparing substituted quinazoline derivatives | |
ES2255973T3 (en) | PREPARATION OF SULFONAMIDS. | |
ES2208167T3 (en) | PROCEDURE FOR THE PREPARATION OF N- (5-DIFENYL-PHOSPHINOYLMETHYL) -4- (4-FLUOROPHENYL) -6-ISOPROPILPIRIMIDIN-2-IL) -N-METHYLMETHANE-SULFONAMIDE. | |
CN103930400B (en) | Prepare method and the intermediate of 1-acyl-4-phenyl alkylsulfonyl Prolinamide derivatives | |
BR112020020549A2 (en) | NEW PROCESS FOR THE SYNTHESIS OF A DIAMINOPYRIMIDINE PHENOXY COMPOUND | |
ES2251392T3 (en) | PROCEDURE TO PREPARE 2-AMINO-4- (4-FLUOROPHENYL) -6-ALKYL PYRIMIDINE-5-CARBOXYLATES. | |
ES2302694T3 (en) | PROCEDURE FOR THE PREPARATION OF (1R, 2S, 4R) - (-) - 2- (2'-N, N-DIMETHYLAMIN-ETOXI) -2-PHENYL-1,7,7-TRI-METHYL-BIKE 2.2.1 HEPTANO AND ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS. | |
KR20200024252A (en) | Substituted Quinolinylcyclohexylpropanamide Compounds and Improved Methods of Making the Same | |
KR101803499B1 (en) | Novel process for preparing thienopyrimidine compound and intermediates used therein | |
TWI383974B (en) | Method for preparing (3s,4s)-4-((r)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor | |
US20170022169A1 (en) | Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom | |
JPH06100540A (en) | 5-isoquinolinesulfonic acid amide derivative | |
JP2007517797A (en) | Preparation of highly chemical R-5- (2- (2-ethoxyphenoxyethylamino) propyl) -2-methoxybenzenesulfonamide hydrochloride | |
ES2364350T3 (en) | PROCEDURE FOR THE PREPARATION OF 1-METHYLINDAZOL-3-CARBOXYL ACID. | |
US6160115A (en) | Process for preparing N-[5-(diphenylphosphinoylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin -2-yl]-N-methylmethanesulfonamide | |
EP1002798A1 (en) | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative | |
CN107434807A (en) | A kind of preparation method of the azaindole of 5 hydroxyl 7 | |
ES2204950T3 (en) | INTERMEDIATE PRODUCT TO PREPARE A PHARMACEUTICALLY ACTIVE COMPOUND. | |
CN106749266B (en) | The high efficiency preparation method of pyrrolo- [2,3-d] pyrimidines | |
WO2012022217A1 (en) | N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide derivatives, a preparation method and use for synthesis of imatinib thereof |